MAVYRET
-
AbbVie Partnered with Enanta Pharmaceuticals, Receives FDA Approval for Expanded MAVYRET® Use: First and Only Acute Hepatitis C Treatment
Enanta Pharmaceuticals (ENTA) announced FDA approval for MAVYRET (glecaprevir/pibrentasvir), now the only eight-week oral treatment for acute HCV in adults and children (3+ years). The approval allows providers to immediately treat diagnosed HCV patients with a 96% cure rate. This breakthrough aims to prevent chronic disease progression and supports the global public health goal of HCV elimination by 2030.
